BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
235 hedge funds and large institutions have $5.86B invested in bluebird bio in 2015 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 71 increasing their positions, 88 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
4% more call options, than puts
Call options by funds: $117M | Put options by funds: $112M
19% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 88
Holders
235
Holding in Top 10
8
Calls
$117M
Puts
$112M
Top Buyers
| 1 | +$406M | |
| 2 | +$116M | |
| 3 | +$109M | |
| 4 |
O
OrbiMed
New York
|
+$68.6M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$66.1M |
Top Sellers
| 1 | -$101M | |
| 2 | -$69.1M | |
| 3 | -$51.3M | |
| 4 |
UBS AM
Chicago,
Illinois
|
-$48.3M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$38.4M |